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were based on the 2013 utilisation volume data. Other local specific considerations 
e.g. subsidized selling prices and co-payments were included in the analyses for an 
assumed size of eligible patients. Sensitivity analyses were conducted. Results: 
The adoption rates of BIAsp were assumed to increase from 23.6% in 2013 to 30% 
or 36.5% in 2018 for base case and upside scenario, respectively. In comparison 
to base case scenario, increases in adoption rate of BIAsp were associated with a 
cumulative increase up to slightly greater than S$ 2.02M in insulin acquisition cost 
but a potential cumulative net saving up to approximately S$0.92M in overall total 
costs over 5 years, attributing to subsidized selling price of BIAsp assuming it is 
included standard drug list and its significantly lower major hypoglycaemia risk, 
respectively. Cost savings were predicted for other complications. ConClusions: 
The wider adoption of BIAsp was predicted to result in net cost savings from patient 
perspective in Singapore. More cost saving would be estimated in analyses with 
reduced productivity loss from a societal perspective.
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objeCtives: Patient-driven titration has been proven as efficacious and safe as physi-
cian-driven titration of Biphasic Insulin Aspart 30 (BIAsp 30) in people with type 2 dia-
betes (T2DM) in China in the 20-week trial (ClinicalTrials.gov identifier: NCT01618214). 
This study was to further compare titration-related health care utilizations and costs 
associated with BIAsp 30 self-driven versus physician-driven titration in China based 
on this trial. Methods: 344 eligible premixed/self-mixed human insulin users with 
T2DM were randomly assigned to BIAsp 30 twice daily either with self-driven or 
physician-driven titration. Mean number of self-measured plasma glucose (SMPG), 
clinical visits and phone contacts with health care practitioners (HCPs) due to insu-
lin-titration were recorded in the trial and used to evaluate health care utilization. 
Costs were calculated from a societal perspective, including: 1) direct medical costs, 
multiplying utilizations in the trial and unit cost reported in the literature; 2) direct 
non-medical costs as transportation fees from previous studies; and 3) indirect costs 
estimated by human capital approach. Results: During the 20-week trial period, 
health care utilization associated with self-driven titration was lower than that with 
physician-driven titration (mean number of SMPG was 147.15 versus 151.31(P= 0.5178), 
outpatient visits was 5.69 versus 8.86 (P< 0.001), calls was 5.94 versus 5.98 (P= 0.1956), 
and there were no titration-related hospitalizations in both groups). Average total 
titration-related costs were CNY 424.93 lower in self-driven group than in physician-
driven group (total cost was CNY 1654.14 versus CNY 2079.07; direct medical cost 
was CNY 1151.31 versus CNY 1329.06; transportation cost was CNY 360.61 versus 
CNY 537.88; and indirect cost was CNY 142.22 versus CNY 212.13). ConClusions: 
Self-driven titration of BIAsp 30 was associated with less health care utilization and 
lower costs compared to physician-driven titration in people with T2DM in China. 
The new evidence suggests that a more patient-focused approach towards diabetes 
management may be cost-saving and improve overall efficiency.
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objeCtives: To perform a partial economic evaluation of Type 2 Diabetes 
Mellitus (DM2) as well as its micro and macrovascular complications from the 
institutional point of view. (Social Security Costarican Register (CCSR)), for the 
year 2013. Methods: A partial economic evaluation evaluation analysis was used 
to analyse the average annual cost for DM2 in costarrican patients. The analysis 
pays special attention related to the sickness (cardiovascular, renal, microvascular, 
ophthalmic complications and acute events). Costarrican literature was reviews 
to obtain costs for DM2 as for its complications, also clinical practice guides for 
the use of resources were used and finally, this information was validated with 
specialist physicians from Costa Rica. Only direct medical costs were used, such as: 
medications, laboratory and additional studies, medical consults, hospitalizations 
and material; these were obtained from the Cost Model 2013 of the CCSR such as 
the Statistical Annual Yearbook. To prove the strength of the analysis, deterministic 
and probabilistic sensitivity tests were performed. Results: The average annual 
cost for DM2 for the year 2013 in Costa Rica was USD $1,466.17. The macro and 
microvascular complications related to DM2 were more expensive in 2013 for Costa 
Rica were the following: USD $105,865.80 for haemodyalisis during the first year, USD 
$21,600.40 for chronic cardiac failure during the first year, USD $15,414.40 for acute 
myocardial infarction and USD $15,025.39 for amputation. An average, hospitaliza-
tions represented a 27% of the resources used for treatment of complications. The 
sensitivity analysis proved the strength of the costs. ConClusions: Despise the 
lack of information in the literature, this article is the first approximation of costs 
on DM2 and its complications in Costa Rica for the year 2013.
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Among 150 (14.5%) patients who died during hospitalization, 102(68.0%) patients 
have used HES. and 105 (70.0%) patients were males. Multivariate logistic regres-
sion suggested that patients who ever used HES were associated with higher risk 
of mortality (adjusted odds ratio, AOR: 1.60; 95%CI: 1.04-2.45) even after adjusting 
for IHD (AOR: 1.64; 95%CI: 0.98-2.74), CRF (AOR: 4.28; 95%CI: 2.35-7.79), high blood 
glucose (AOR: 2.85; 95%CI: 1.83-4.45), AKI during hospitalization (AOR: 4.30; 95%CI: 
2.79-6.62). ConClusions: Use of HES may be independently associated with higher 
risk of death in ICU patients with diabetes. However, further studies are required to 
demonstrate the causation of HES and hospitalized mortality.
DiaBetes/enDoCrine DisorDers – Cost studies
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objeCtives: Budget impact analysis (BIA) is a useful tool for reimbursement 
decision-makers in health technology assessments by authorities across different 
countries. This study aimed to evaluate the financial impact from the Ministry of 
Health (MOH) perspective of different adoption rates of Biphasic Insulin Aspart 
(BIAsp) versus Biphasic Human Insulin (BHI) in treating type 2 diabetes melli-
tus. Methods: An Excel based 5-year budget impact model was built to estimate 
insulin treated patients by public providers using local prevalence data. The pub-
lished demographic, efficacy and adverse event data for ASEAN subgroup analyses 
of A1chieve study was applied. Both insulin acquisition costs and other medical 
costs for complications e.g. major hypoglycaemia, myocardial infarction, stroke, 
end-stage renal disease, blindness and amputation were included at a discount rate 
of 3%. The incidence rates of these complications were derived from the established 
UKPDS equations. The adoption rates were assumed and projected from the 2013 
utilisation volume data of BIAsp and BHI by public providers. Sensitivity analyses 
were conducted. Results: The adoption rates of BIAsp were assumed to increase 
from 1.8% in 2013 to 4.5% or 6.9% in 2018 for base case and upside scenario, respec-
tively. Compared to the base case, upside scenario of wider BIAsp adoption was 
associated with an increased insulin cost up to RM 8.2M which was offset by avoided 
complication costs resulting in an overall net budget saving of approximately RM 
5.5M over 5 years, primarily driven by estimated reduction in major hypoglycae-
mia events for patients treated with BIAsp. ConClusions: The higher and wider 
adoption of BIAsp would likely be associated with cost savings in Malaysia from the 
MOH perspective attributed to its superiority in H1Ac reduction and lower major 
hypoglycemia risk in comparison to BHI. More cost saving would be concluded if 
productivity loss is included from a societal perspective.
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objeCtives: To estimate the budget impact of switching to U100 insulin (100 units 
[U]/ml) in Egyptian diabetic patients over a time horizon of 5 years. Methods: 
Pharmacy and medical budget impacts were estimated over the first 5 years of 
U100 insulin use in diabetic patients from the Egyptian health care system’s per-
spective. Local epidemiology data were used to estimate target population size. 
Pre-U100 insulin entry treatment option included U40 insulin (40 units [U]/ml). 
Pre- and post-U100 insulin entry market shares were estimated based on market 
research and assumptions. Direct medical costs were derived from the Ministry of 
Health tender list. All costs were reported in Egyptian pounds of the financial year 
2014. Deterministic sensitivity analysis was conducted. Results: In a hypotheti-
cal 85,294,388-member plan, 1,234,380 patients were expected to be candidates for 
U100 insulin treatment in type I and type II diabetes. The total budget impact after 
5 years post-U100 insulin was EGP -0.049 per member per month [PMPM] (pharmacy 
budget: EGP -0.047 PMPM; medical budget: EGP -0.002 PMPM), assuming 53.59% of the 
target population would switch to U100 insulin. Sensitivity analyses determined that 
the cost of U40 insulin and U100 insulin had the potential to impact the base case 
analysis. ConClusions: The total budget for diabetes following U100 insulin use 
were cost-saving in comparison to U40 insulin. Conversion to U100 insulin would 
result in lower overall treatment costs in patients with diabetes from the health 
care system’s perspective. An intensive information campaign providing detailed 
advice for patients, physicians and pharmacists is essential for the prevention of 
medication errors and reduction of overall costs.
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objeCtives: Economic evaluations of BIAsp have been published in the context 
of different countries. This study aimed to evaluate the financial impact from a 
perspective of patients treated by public providers of different adoption rates of 
Biphasic Insulin Aspart (BIAsp; NovoMix 30 FlexPen®) versus Biphasic Human 
Insulin (BHI; Mixtard Penfill®) in treating T2DM. Methods: An Excel based 5-year 
budget impact model was built to estimate insulin treated patients by public pro-
viders using the local prevalence data. The published demographic, efficacy and 
adverse event data for ASEAN subgroup analyses of A1chieve study was applied. 
Both insulin acquisition costs and medical costs for major hypoglycaemia and other 
complications were applied with a 3% discount rate to the estimated corresponding 
incidence rates derived from the UKPDS equations. The projected adoption rates 
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the patients with high blood-sugar levels visit doctors retrospectively, its monthly 
medical cost would have been 4.12 million yen lower now, which represents 412 
yen a month per member.
PDB21
CliniCal effiCaCy anD Costs of insUlin analogUe ComPareD to 
HUman insUlin in Patients witH DiaBetes: resUlts from a tertiary 
HosPital in Beijing
Guan X1, Xu Z1, Hu C2, Wu J3
1The 306th Hospital of PLA, Beijing, China, 2Peking University Health Science Centre, Beijing, 
China, 3Pharmacoeconomics Committee of Chinese Pharmaceutical Association, Beijing, China
objeCtives: This study aims to compare clinical efficacy and costs between insulin 
analogue and human insulin in treatment of patients with diabetes in a tertiary hos-
pital in Beijing. Methods: Data were extracted from inpatient electronic patient 
records in HIS system in a tertiary hospital in Beijing during the period between 
Aug 2011 and Nov 2013. Inclusion criteria: main admitting diagnoses were type I 
diabetes or type II diabetes; insulin analogue or human insulin were used during 
hospital stay. Exclusion criteria: combination use of insulin analogue and human 
insulin. Fasting blood-glucose (FPG) before breakfast was used as efficacy index 
while total inpatient expenditure was used as cost index. Unfortunately, HbA1c 
level was unavailable to this study. Student-t test and Chi-square test were con-
ducted using SPSS 20.0. Results: Insulin analogue (n= 50) and human insulin 
(n= 49) cohort had comparable male (68% vs 49%, P= 0.055), age (50 vs 57, P= 0.008), 
and baseline clinical characteristics (length of stay 10 vs 11, P= 0.133; baseline FPG 
8.73mmol/L vs 8.44mmol/L, P= 0.630). At the point of discharge, FPG before breakfast 
was dropped to 6.39mmol/L vs 7.13mmol/L (P= 0.025) in insulin analogue and human 
insulin cohort, respectively. The total medical costs were CNY 11,305 vs CNY 10,693 
(P= 0.577), and total drug costs were CNY 5,198 vs CNY 4,199 (P= 0.186), in insulin 
analogue and human insulin cohort, respectively. ConClusions: Insulin analogue 
treated patients experienced significantly greater reductions in FPG before breakfast 
compared to human insulin treated patients, while total inpatient expenditure and 
drug costs showed no significant difference between the two cohorts. Should data 
permits, HbA1c data should be included in further analysis in the future.
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objeCtives: To evaluate the cost, cost-effectiveness and cost-benefit of clinical 
pharmacy service for diabetic patients on view of hospital. Methods: A prospec-
tive study was conducted at a provincial hospital in Sichuan, China. Inpatients 
with a diagnosis of diabetes were enrolled in the study during 2010.03 -2011.06. 
Patients were divided into intervention group(121) and control group(122) randomly 
when admitted. Intervention group equipped a clinical pharmacist providing clini-
cal pharmacy services during therapy, the control group took routinely pharmacy 
service. The times of avoiding medicine errors were counted as effectiveness, the 
saving of patients’ expense was calculated as benefit. The cost was calculated by 
routine/clinical pharmacy service spending. Cost-effectiveness and cost-benefit 
analysis were conducted. Results: The average length of stay was 13.82 days in 
intervention group and 14.79 days in control group(P> 0.05). Average 337 minutes(5.6 
hours) was spent in daily clinical pharmacy services in intervention group. The cost 
of routine pharmacy service in control group was 729.05$(daily salary* average stay 
length of patients), while clinical pharmacy services cost in intervention group was 
estimated as 1175.82$(routine pharmacy service cost+ training cost+ clinical phar-
macy services cost), 446.77$ more than routine(theoretically, didn’t actually happen). 
The average percentage of avoiding medicine errors was 64.19% in intervention 
groups and 3.54% in control group(total suggestion times for adjusting drug schemes 
/total medical orders), accordingly the cost-effectiveness of avoiding medicines 
errors(C/E) in intervention group was 18.32 while 209.95 in control group. The aver-
age admission expense was 1703.80$ in intervention group and 1959.50$ in control 
group(P< 0.05), so average saving expense of patients under clinical pharmacy inter-
vention was 255.69$. Comparing with the extra possible input of providing clinical 
pharmacy service, the net benefit was -191.08$. ConClusions: Clinical pharmacy 
service do play a significant role in avoiding medicine errors and reducing patient 
expenses, if didn’t consider the time and labor cost of clinical pharmacist.
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objeCtives: To evaluate the long-term economic and health outcomes associated 
with once daily liraglutide 1.2 mg, the most frequently prescribed dosage in China, 
versus twice daily exenatide 10 μ g prescribed according to National Institute for 
Health and Clinical Excellence recommendations in clinical practice in patients with 
Type 2 Diabetes Mellitus (T2DM). Methods: A published and validated computer 
simulation model (CORE Diabetes Model) was used to make the projection of 30-year 
long-term economic and health outcomes. Simulated cohorts and treatment effects 
were derived from results of a retrospective chart audit with a median follow-up of 
48 weeks including 256 patients receiving liraglutide and 148 receiving exenatide. 
Treatment costs were derived from drug retail prices in Chinese market. The dia-
betes management and complication costs were obtained from Chinese published 
data. Projections were made from a societal perspective with an annual discounting 
rate of 3%. One-way sensitivity analyses were performed. Results: Long term pro-
jections demonstrated that compared with exenatide, liraglutide 1.2 mg was asso-
ciated with lower cumulative incidences of diabetes complications and improved 
objeCtives: To explore medical expenditure and its impact for people with diabetes 
covered by Urban Employee Basic Medical Insurance for Hebei Provincial Institutes 
(UEBMIHPI). Methods: People diagnosed with “diabetes” were identified from 
UEBMIHPI claims database during Dec 30th, 2010 and Dec 25th, 2011. The Sum_All 
Medical method was used for expenditure estimation. Descriptive analyses were 
conducted using EXCEL 2010. Results: During Dec 30th, 2010 and Dec 25th, 2011, 
the UEBMIHPI database recorded claims data of 110256 patients, including 7944 with 
diabetes (7.21% of all patients), among which 7421 had outpatient records (7.24% 
of all outpatients) and 2964 had inpatient records (12.16% of all inpatients). 63.28% 
were male and 79.51% were 50 years of age or older. Mean number of outpatient 
visits was 14.04 for people with diabetes, in comparison with 4.12 for outpatient 
with other diseases. Outpatient treatment cost was CNY 9332.52/person and CNY 
724.99/visit, of which 30.59% were out-of-pocket money. For those who had used 
inpatient services, annual inpatient admissions were 1.67 times/person and the cost 
was CNY 23494.63/person and CNY 14109.20/hospital stay. Over 60% hospitaliza-
tions happened in tertiary hospitals. People with diabetes consumed 21.59% (CNY 
139million) of total medical expenditure. Only CNY 21 million (15.42%) was spent 
on anti-glycaemic treatments, the cost of OAD, insulin, insulin pump and Chinese 
traditional drugs accounted for 52.27%, 40.75%, 2.62% and 4.36% respectively. People 
with diabetes who received diagnoses or treatments for diabetic complications 
consumed more health care resources (physician visit, medical expenditure/person 
and medical expenditure/visit) than others. ConClusions: As one of the major 
chronic diseases, diabetes consumed great health care resources in Hebei. Majority 
of direct medical expenditures were spent on treating diabetes-related diseases. 
Perhaps to reduce risks of diabetes complications by promoting early diagnosis, 
early treatment, rational drug utilization and disease control is the way to save 
health care and social resources.
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objeCtives: To collate published evidence evaluating economic implications of 
chronic renal disease (CRD) with and without co-morbid diabetes mellitus in China 
(post-2005). Methods: A systematic search of electronic databases (Embase® and 
MEDLINE®) was conducted from January 2005 to March 2014 to identify economic 
studies in English evaluating CRD with and without co-morbid diabetes mellitus in 
China. Results: Five studies (all cost of illness, CRD [n= 3] and CRD with co-morbid 
diabetes [n= 2]) of 134 citations retrieved, met pre-defined inclusion criteria. In 2012, 
total cost/patient for stage-3/4 CRD was Chinese Yuan (CYN) 34205 with 97.75% 
being direct cost, while for stage-5 CRD the corresponding values were CYN128231 
and 82.3%, respectively (Wu 2013). In the study by Zhang and colleagues, patients 
undergoing haemodialysis (HD) incurred 16% higher costs relative to those undergo-
ing peritoneal dialysis (PD) in 2010 (p= 0.01). Further, patients with comorbid diabe-
tes incurred higher total costs compared to their CRD alone counterparts (p= 0.03) 
(Zhang 2012). Among patients with CRD in northwest China observed between 
March 2007 and February 2008, the first, second, and third year renal transplant 
(RT)/HD costs were CYN201674/CYN94136, CYN71746/CYN87765, and CYN66851/
CYN86987, respectively indicating higher efficacy and lower costs of RT than HD 
from second year onwards (Xiaoming 2012). These findings were consistent with 
those reported in another study; in 2011 the direct cost of diabetes-associated renal 
failure with HD/PD was CYN72761.17/CYN470764.77 and RT was CYN218508.075 
(Zheng 2012). Among diabetic patients with comorbid CRD, direct cost in 2007 was 
CYN1308.07 million, while corresponding cost projected in 2030 increased two-fold 
to CYN2351.60 million (Wang 2009). ConClusions: CRD consumes a large portion 
of health care expenditures (with direct medical cost being main cost driver) and 
is projected to exert heavy burden on health budget in future as well. Additionally, 
patients with comorbid diabetes incurred higher costs relative to their CRD alone 
counterparts.
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objeCtives: We define patients who have not consulted doctors to treat their 
diabetes, while they have learned their blood-sugar levels are high through health 
check-up, as untreated-diabetes patients. Our research objective is to calculate 
using real world data how much lower the medical cost would be if the untreated-
diabetes patients visit doctors in response to suggestions to do, which represents 
the cost reduction of cost-effectiveness analysis. Methods: We used the data 
of Japan Medical Data Center (JMDC), which provides health insurance claims 
data with linked health check-up data of 1.7 million members from health insur-
ance societies in Japan. Results: It is estimated there are 71 untreated-diabetes 
patients in a virtual (yet supposed-to-be typical according to the JMDC data) health 
insurance society with 10,000 members. And 16% of them would visit doctors 
within 3 months, while remaining 84% would leave their conditions as they are 
for averagely 40 months knowing that their blood-sugar levels are high. It is nec-
essary to advise untreated-diabetes patients to visit doctors for treatment. Such 
advices should be able to start their diabetes treatment in early stages and prevent 
them from future complicating diseases. According to our calculation, the medical 
cost after its diagnosis would increase by 1.1% without aging factors by leaving 
their untreated-diabetes conditions for one month. ConClusions: If the virtual 
health insurance society had all the existing 71 untreated-diabetes patients visit 
doctors right now, their monthly medical cost would be 0.37 million yen lower 
against the amount they had to pay in the future (averagely in 20 months) if they 
continue to avoid visiting, which represents 37 yen a month per member, and all 
